Technical Analysis for ANIX - Anixa Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Calm After Storm | Range Contraction | 4.57% | |
| Upper Bollinger Band Walk | Strength | 4.57% | |
| Inside Day | Range Contraction | 4.57% | |
| Wide Bands | Range Expansion | 4.57% | |
| Down 3 Days in a Row | Weakness | 4.57% | |
| Stochastic Sell Signal | Bearish | 1.95% | |
| Golden Cross | Bullish | 1.95% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 22 hours ago |
| Up 5% | about 22 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Up 3% | about 23 hours ago |
| Up 2% | about 24 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/07/2024
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.13 |
| 52 Week Low | 2.145 |
| Average Volume | 68,585 |
| 200-Day Moving Average | 3.22 |
| 50-Day Moving Average | 3.26 |
| 20-Day Moving Average | 3.24 |
| 10-Day Moving Average | 3.43 |
| Average True Range | 0.22 |
| RSI (14) | 61.54 |
| ADX | 23.03 |
| +DI | 29.04 |
| -DI | 18.82 |
| Chandelier Exit (Long, 3 ATRs) | 3.44 |
| Chandelier Exit (Short, 3 ATRs) | 3.59 |
| Upper Bollinger Bands | 3.85 |
| Lower Bollinger Band | 2.62 |
| Percent B (%b) | 0.84 |
| BandWidth | 38.07 |
| MACD Line | 0.13 |
| MACD Signal Line | 0.06 |
| MACD Histogram | 0.0669 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.89 | ||||
| Resistance 3 (R3) | 3.88 | 3.79 | 3.85 | ||
| Resistance 2 (R2) | 3.79 | 3.74 | 3.80 | 3.83 | |
| Resistance 1 (R1) | 3.73 | 3.70 | 3.76 | 3.74 | 3.82 |
| Pivot Point | 3.64 | 3.64 | 3.66 | 3.65 | 3.64 |
| Support 1 (S1) | 3.58 | 3.59 | 3.61 | 3.59 | 3.50 |
| Support 2 (S2) | 3.49 | 3.55 | 3.50 | 3.49 | |
| Support 3 (S3) | 3.43 | 3.49 | 3.47 | ||
| Support 4 (S4) | 3.44 |
